These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 38334258)

  • 1. Efficacy of the iron-chelating agent, deferiprone, in patients with Parkinson's disease: A systematic review and meta-analysis.
    Negida A; Hassan NM; Aboeldahab H; Zain YE; Negida Y; Cadri S; Cadri N; Cloud LJ; Barrett MJ; Berman B
    CNS Neurosci Ther; 2024 Feb; 30(2):e14607. PubMed ID: 38334258
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Trial of Deferiprone in Parkinson's Disease.
    Devos D; Labreuche J; Rascol O; Corvol JC; Duhamel A; Guyon Delannoy P; Poewe W; Compta Y; Pavese N; Růžička E; Dušek P; Post B; Bloem BR; Berg D; Maetzler W; Otto M; Habert MO; Lehericy S; Ferreira J; Dodel R; Tranchant C; Eusebio A; Thobois S; Marques AR; Meissner WG; Ory-Magne F; Walter U; de Bie RMA; Gago M; Vilas D; Kulisevsky J; Januario C; Coelho MVS; Behnke S; Worth P; Seppi K; Ouk T; Potey C; Leclercq C; Viard R; Kuchcinski G; Lopes R; Pruvo JP; Pigny P; Garçon G; Simonin O; Carpentier J; Rolland AS; Nyholm D; Scherfler C; Mangin JF; Chupin M; Bordet R; Dexter DT; Fradette C; Spino M; Tricta F; Ayton S; Bush AI; Devedjian JC; Duce JA; Cabantchik I; Defebvre L; Deplanque D; Moreau C;
    N Engl J Med; 2022 Dec; 387(22):2045-2055. PubMed ID: 36449420
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Brain iron chelation by deferiprone in a phase 2 randomised double-blinded placebo controlled clinical trial in Parkinson's disease.
    Martin-Bastida A; Ward RJ; Newbould R; Piccini P; Sharp D; Kabba C; Patel MC; Spino M; Connelly J; Tricta F; Crichton RR; Dexter DT
    Sci Rep; 2017 May; 7(1):1398. PubMed ID: 28469157
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ceruloplasmin activity and iron chelation treatment of patients with Parkinson's disease.
    Grolez G; Moreau C; Sablonnière B; Garçon G; Devedjian JC; Meguig S; Gelé P; Delmaire C; Bordet R; Defebvre L; Cabantchik IZ; Devos D
    BMC Neurol; 2015 May; 15():74. PubMed ID: 25943368
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting chelatable iron as a therapeutic modality in Parkinson's disease.
    Devos D; Moreau C; Devedjian JC; Kluza J; Petrault M; Laloux C; Jonneaux A; Ryckewaert G; Garçon G; Rouaix N; Duhamel A; Jissendi P; Dujardin K; Auger F; Ravasi L; Hopes L; Grolez G; Firdaus W; Sablonnière B; Strubi-Vuillaume I; Zahr N; Destée A; Corvol JC; Pöltl D; Leist M; Rose C; Defebvre L; Marchetti P; Cabantchik ZI; Bordet R
    Antioxid Redox Signal; 2014 Jul; 21(2):195-210. PubMed ID: 24251381
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanism Underlying the Effectiveness of Deferiprone in Alleviating Parkinson's Disease Symptoms.
    Sun Y; Pham AN; Waite TD
    ACS Chem Neurosci; 2018 May; 9(5):1118-1127. PubMed ID: 29381045
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantifying iron deposition within the substantia nigra of Parkinson's disease by quantitative susceptibility mapping.
    An H; Zeng X; Niu T; Li G; Yang J; Zheng L; Zhou W; Liu H; Zhang M; Huang D; Li J
    J Neurol Sci; 2018 Mar; 386():46-52. PubMed ID: 29406966
    [TBL] [Abstract][Full Text] [Related]  

  • 9. No difference in myocardial iron concentration and serum ferritin with deferasirox and deferiprone in pediatric patients with hemoglobinopathies: A systematic review and meta-analysis.
    Saleem A; Waqar E; Shuja SH; Naeem U; Moeed A; Rais H; Ahmed J
    Transfus Clin Biol; 2023 Feb; 30(1):69-74. PubMed ID: 35878782
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia.
    Fortin PM; Fisher SA; Madgwick KV; Trivella M; Hopewell S; Doree C; Estcourt LJ
    Cochrane Database Syst Rev; 2018 May; 5(5):CD012349. PubMed ID: 29737522
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A systematic review and meta-analysis of deferiprone monotherapy and in combination with deferoxamine for reduction of iron overload in chronically transfused patients with β-thalassemia.
    Kuo KH; Mrkobrada M
    Hemoglobin; 2014; 38(6):409-21. PubMed ID: 25307964
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia.
    Geneen LJ; Dorée C; Estcourt LJ
    Cochrane Database Syst Rev; 2023 Mar; 3(3):CD012349. PubMed ID: 36877640
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Parkinson's disease related signal change in the nigrosomes 1-5 and the substantia nigra using T2* weighted 7T MRI.
    Schwarz ST; Mougin O; Xing Y; Blazejewska A; Bajaj N; Auer DP; Gowland P
    Neuroimage Clin; 2018; 19():683-689. PubMed ID: 29872633
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and efficacy of deferiprone for pantothenate kinase-associated neurodegeneration: a randomised, double-blind, controlled trial and an open-label extension study.
    Klopstock T; Tricta F; Neumayr L; Karin I; Zorzi G; Fradette C; Kmieć T; Büchner B; Steele HE; Horvath R; Chinnery PF; Basu A; Küpper C; Neuhofer C; Kálmán B; Dušek P; Yapici Z; Wilson I; Zhao F; Zibordi F; Nardocci N; Aguilar C; Hayflick SJ; Spino M; Blamire AM; Hogarth P; Vichinsky E
    Lancet Neurol; 2019 Jul; 18(7):631-642. PubMed ID: 31202468
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Meta-Analysis of Creatine for Neuroprotection Against Parkinson's Disease.
    Attia ; Ahmed H; Gadelkarim M; Morsi M; Awad K; Elnenny M; Ghanem E; El-Jaafary S; Negida A
    CNS Neurol Disord Drug Targets; 2017; 16(2):169-175. PubMed ID: 27823574
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral deferiprone for iron chelation in people with thalassaemia.
    Fisher SA; Brunskill SJ; Doree C; Chowdhury O; Gooding S; Roberts DJ
    Cochrane Database Syst Rev; 2013 Aug; (8):CD004839. PubMed ID: 23966105
    [TBL] [Abstract][Full Text] [Related]  

  • 17. GLP-1 receptor agonists for Parkinson's disease.
    Mulvaney CA; Duarte GS; Handley J; Evans DJ; Menon S; Wyse R; Emsley HC
    Cochrane Database Syst Rev; 2020 Jul; 7(7):CD012990. PubMed ID: 32700772
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overall Efficacy and Safety of Safinamide in Parkinson's Disease: A Systematic Review and a Meta-analysis.
    Giossi R; Carrara F; Mazzari M; Lo Re F; Senatore M; Schicchi A; Corrù F; Fittipaldo VA; Pani A; Tramacere I; Elia AE; Scaglione F
    Clin Drug Investig; 2021 Apr; 41(4):321-339. PubMed ID: 33674954
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Deferasirox for managing iron overload in people with thalassaemia.
    Bollig C; Schell LK; Rücker G; Allert R; Motschall E; Niemeyer CM; Bassler D; Meerpohl JJ
    Cochrane Database Syst Rev; 2017 Aug; 8(8):CD007476. PubMed ID: 28809446
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Motor associations of iron accumulation in deep grey matter nuclei in Parkinson's disease: a cross-sectional study of iron-related magnetic resonance imaging susceptibility.
    Martin-Bastida A; Lao-Kaim NP; Loane C; Politis M; Roussakis AA; Valle-Guzman N; Kefalopoulou Z; Paul-Visse G; Widner H; Xing Y; Schwarz ST; Auer DP; Foltynie T; Barker RA; Piccini P
    Eur J Neurol; 2017 Feb; 24(2):357-365. PubMed ID: 27982501
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.